Evofem Biosciences

191 articles about Evofem Biosciences

• Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023

  6/1/2023

  Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced strong preliminary results for the first quarter of 2023, including robust growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

• Evofem Biosciences Announces 1-for-125 Reverse Stock Split

  5/17/2023

  Evofem Biosciences, Inc., announced a 1-for-125 reverse stock split of the Company's common stock, which was approved by the stockholders of the Company at the special meeting of stockholders held on March 15, 2023.

• Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update

  4/28/2023

  In 2022, we more than doubled Phexxi revenue while cutting costs 42%. That was good, but not enough to get us to break-even.

• Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

  4/14/2023

  Evofem Biosciences, Inc., the maker of Phexxi®, announced the appointment of Ivy Zhang as Chief Financial Officer and Secretary, effective April 13, 2023.

• Evofem Biosciences Announces Cost Reduction Measures

  3/21/2023

  Evofem Biosciences, Inc. , (OTCQB: EVFM) (the "Company") today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023.

• Evofem Biosciences Appoints Interim Chief Financial Officer

  3/9/2023

  Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company.

• Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

  2/27/2023

  Evofem Biosciences, Inc. (OTCQB: EVFM ) today announced that two additional U.S. patents which cover  Phexxi®  (lactic acid, citric acid and potassium bitartrate ) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

• Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value

  2/23/2023

  Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic alternatives to maximize shareholder value.

• Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)

  1/12/2023

  Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of Phexxi®  (lactic acid, citric acid and potassium bitartrate).

• OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

  12/29/2022

  Evofem Biosciences, Inc. announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

• Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

  10/11/2022

  Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.

• Evofem Biosciences Announces Approval of Phexxi in Nigeria

  10/6/2022

  Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). 

• Evofem Biosciences Announces Uplisting to OTCQB

  10/3/2022

  Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market.

• 

  A Comprehensive Guide to Success for Women in the Life Sciences

  9/26/2022

  BioSpace spoke with Saundra Pelletier, CEO of Evofem Biosciences, to discuss the realities of being a woman in the life sciences and find out the career moves that propelled her forward.

• Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter

  9/23/2022

  Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).  

• Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

  9/16/2022

  Evofem Biosciences, Inc. announced another new insurance win that gives millions of additional women access to Phexxi® for the prevention of pregnancy.

• Evofem Announces Successful Debt Restructuring

  9/16/2022

  Evofem Biosciences, Inc. announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.

• Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance

  8/4/2022

  Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.

• Evofem Biosciences Strengthens Board of Directors

  8/3/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip , a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors.

• Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women

  8/1/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women.